Contrary to TasP, PrEP is an individual preventive intervention for which the coverage level is of less importance. However, as the investigators are expecting that at least 60% of HIV-negative FSWs will accept PrEP, it may also have preventive benefits at the overall FSW population level. We have decided to combine TasP and PrEP in the same project for efficiency and ethical reasons. Indeed, this approach implies that all FSWs consulting at the project clinics will be offered some form of antiretroviral drugs with provision of adherence counseling. In addition, on an ethical point of view and considering the community perspective, it would be difficult to justify an approach where antiretroviral drugs would be given to HIV-negative women while asymptomatic HIV-positive FSWs with >350 CD4/mm³ are not treated. Note that according to the current Benin national guidelines, ART is provided for free to HIV-infected subjects with CD4<350 CD4/mm³, but this could change during the course of the study following the recently revised WHO guidelines proposing a threshold of 500 CD4/mm³ for treatment eligibility.